# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of p...
Foundation Medicine, Inc., today announced that it has formed a collaboration with Repare Therapeutics, a leading clinical-sta...
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology...
HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $10 price...
HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $10 price...
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology...